Buy DXCM by Nov 22, 2026.

Looking into DexCom (DXCM). The stock has dropped significantly but if you do a full analysis (researching both its competitors and running the DCF model) there's still about 12% upside in a base case, and 20% upside based on current cash flow (only about .9% in a bear case). There are obviously more factors that go into it, but basically: based on growth trends in revenue as well as consistent margins, competitive positioning against its main competitor (Abbott laboratories) and …